Identification

Name
Pipamperone
Accession Number
DB09286
Type
Small Molecule
Groups
Approved, Investigational
Description

Pipamperone is a typical antipsychotic of the butyrophenone family used in the treatment of schizophrenia. It was discovered at Janssen Pharmaceutica in 1961, and entered clinical trials in the United States in 1963 [11, 15].

In an effort to improve haloperidol's pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic drugs at this time, had significant anti-tryptamine activity. Some studies suggest pipamperone was the first atypical antipsychotic. Interestingly, when risperidone was created, Janssen suggested it was a more potent version of pipamperone. Synthesized in the year 1984, risperidone’s pharmacological properties were similar to pipamperone’s in that both block more serotonin more potently than dopamine [15].

Structure
Thumb
Synonyms
  • Carpiperone
  • Floropipamide
  • Fluoropipamide
Product Ingredients
IngredientUNIICASInChI Key
Pipamperone hydrochlorideIT085U64JB2448-68-2BMXXSXQVMCXGJM-UHFFFAOYSA-N
International/Other Brands
Dipiperal / Dipiperon / Piperonil / Piperonyl / Propitan / Propitan 10%
Categories
UNII
5402501F0W
CAS number
1893-33-0
Weight
Average: 375.488
Monoisotopic: 375.232205381
Chemical Formula
C21H30FN3O2
InChI Key
AXKPFOAXAHJUAG-UHFFFAOYSA-N
InChI
InChI=1S/C21H30FN3O2/c22-18-8-6-17(7-9-18)19(26)5-4-12-24-15-10-21(11-16-24,20(23)27)25-13-2-1-3-14-25/h6-9H,1-5,10-16H2,(H2,23,27)
IUPAC Name
1'-[4-(4-fluorophenyl)-4-oxobutyl]-[1,4'-bipiperidine]-4'-carboxamide
SMILES
NC(=O)C1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)N1CCCCC1

Pharmacology

Indication

Treatment of chronic psychoses and states of aggressiveness of various origins [12].

Pharmacodynamics

Pipamperone is an antipsychotic medication that has sedative effects, which may be beneficial in the management of agitation and disordered sleep [8]. Pipamperone, showing antidopaminergic and anti-serotonergic properties, has been noted for its anti- agitation effects and for its ability to normalize sleep rhythms in psychiatric patients [5]. One study showed that pipamperone increased the expression of D4 (dopaminergic) receptors, explaining its helpfulness in decreasing positive psychotic symptoms, such as delusions and hallucinations [19].

Mechanism of action

Pipamperone binds mainly to 5-HT2A receptors, with a nearly equal affinity to D4 receptors and a moderate affinity for 5-HT2C, D2, D3, 1- and 2B-adrenoceptors [5].

This drug is a selective 5-HT2A, D1 and D4 antagonist [13]. Extrapyramidal adverse effects also appear to be limited in pipamperone treatment compared to traditional antipsychotic medications due to its high receptor selectivity [11].

Pipamperone has a 15-fold higher affinity for D4 than D2 receptors. It has been suggested that D4 receptors may play a role in the modulation of GABAergic neuronal activity by dopamine [5].

TargetActionsOrganism
UD(2) dopamine receptor
antagonist
Human
U5-hydroxytryptamine receptor 2A
agonist
Human
UAlpha-1 adrenergic receptors
antagonist
Human
UD(4) dopamine receptor
antagonist
Human
UD(1A) dopamine receptor
antagonist
Human
UD(3) dopamine receptorNot AvailableHuman
U5-hydroxytryptamine receptor 2BNot AvailableHuman
UAlpha-2A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Pipamperone is metabolised in the liver [11].

Route of elimination

Mainly via the kidneys [11]

Half life

17-26h [18]

Clearance
Not Available
Toxicity

Ld50 in rats, 48 mg/kg [16]. Prolonged Qtc interval. Monitoring with regular ECGs is recommended [20].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePipamperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetaminePipamperone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetaminePipamperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePipamperone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Pipamperone.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Acebutolol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Pipamperone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Pipamperone.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Pipamperone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Pipamperone.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pipamperone.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Pipamperone.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pipamperone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pipamperone.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Pipamperone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Pipamperone.Approved, Investigational
AmisulpridePipamperone may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pipamperone.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pipamperone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pipamperone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pipamperone.Experimental
AmphetaminePipamperone may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Pipamperone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Pipamperone is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Pipamperone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Pipamperone.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pipamperone.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Pipamperone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Pipamperone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pipamperone.Approved
AtenololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azaperone.Investigational, Vet Approved
AzelastinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Azilsartan medoxomil.Approved, Investigational
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pipamperone.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Pipamperone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Pipamperone.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Pipamperone.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Pipamperone.Approved, Investigational
BenzphetaminePipamperone may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Pipamperone.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Betaxolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Pipamperone.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Pipamperone.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pipamperone.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Pipamperone.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pipamperone.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Pipamperone.Approved, Investigational, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Pipamperone.Approved, Investigational
BuprenorphinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pipamperone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pipamperone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pipamperone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pipamperone is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Pipamperone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pipamperone.Approved, Illicit, Vet Approved
CabergolineThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Cabergoline.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Pipamperone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipamperone.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Pipamperone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pipamperone.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pipamperone.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pipamperone.Approved
CarteololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Carvedilol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pipamperone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Pipamperone.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pipamperone.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Pipamperone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipamperone.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pipamperone.Approved
ChlorphenterminePipamperone may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pipamperone.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipamperone.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pipamperone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Pipamperone.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Pipamperone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Pipamperone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Pipamperone.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clevidipine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pipamperone.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pipamperone.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Pipamperone.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Pipamperone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pipamperone.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pipamperone.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pipamperone.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Pipamperone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Pipamperone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pipamperone.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Pipamperone.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pipamperone.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pipamperone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipamperone.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Pipamperone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Pipamperone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pipamperone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pipamperone.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pipamperone.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Deutetrabenazine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pipamperone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Pipamperone.Approved, Vet Approved
DextroamphetaminePipamperone may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pipamperone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pipamperone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pipamperone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pipamperone.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pipamperone.Approved, Illicit, Investigational, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diclofenamide.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diethyl ether.Experimental
DiethylpropionPipamperone may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pipamperone.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pipamperone.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipamperone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pipamperone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pipamperone.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Pipamperone is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pipamperone.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pipamperone.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pipamperone.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pipamperone.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pipamperone.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pipamperone.Experimental, Illicit
DuloxetinePipamperone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Pipamperone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pipamperone.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pipamperone.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Pipamperone.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Pipamperone.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eltanolone.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Pipamperone.Approved, Investigational, Vet Approved
EntacaponeThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Pipamperone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Pipamperone.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Pipamperone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Pipamperone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pipamperone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pipamperone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pipamperone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etacrynic acid.Approved, Investigational
EthanolPipamperone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pipamperone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pipamperone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pipamperone.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Pipamperone.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pipamperone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pipamperone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Pipamperone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Pipamperone.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Pipamperone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pipamperone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pipamperone.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pipamperone.Approved
FelodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Pipamperone.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Pipamperone.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pipamperone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pipamperone.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Pipamperone.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pipamperone.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Pipamperone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pipamperone.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Pipamperone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pipamperone.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pipamperone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pipamperone.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Pipamperone.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pipamperone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Pipamperone.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Pipamperone.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Pipamperone.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Pipamperone.Approved, Investigational
FurosemideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pipamperone.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Pipamperone.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pipamperone.Approved, Illicit, Investigational
GepefrinePipamperone may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Pipamperone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Pipamperone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Pipamperone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pipamperone.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipamperone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Pipamperone.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pipamperone.Approved, Illicit
HydroxyamphetaminePipamperone may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pipamperone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Pipamperone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Pipamperone.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pipamperone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indapamide.Approved
IndiplonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Indiplon.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Pipamperone.Withdrawn
Iofetamine I-123Pipamperone may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Pipamperone can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pipamperone.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isradipine.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pipamperone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipamperone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pipamperone.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Labetalol.Approved
LacidipinePipamperone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pipamperone.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Pipamperone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pipamperone.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Pipamperone.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pipamperone.Approved
LevodopaPipamperone may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pipamperone.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pipamperone is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pipamperone.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Pipamperone.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Pipamperone.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Pipamperone.Approved, Investigational
LisdexamfetaminePipamperone may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Pipamperone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pipamperone.Illicit
LofexidineThe therapeutic efficacy of Pipamperone can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pipamperone.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pipamperone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Pipamperone.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Lormetazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Losartan.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipamperone.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Pipamperone can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipamperone.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mebicar.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pipamperone.Approved
MedazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Pipamperone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Pipamperone.Approved, Investigational
MephedronePipamperone may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePipamperone may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Pipamperone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Meptazinol.Experimental
MequitazinePipamperone may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Pipamperone.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipamperone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pipamperone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pipamperone.Approved, Illicit
MethamphetaminePipamperone may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipamperone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Pipamperone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipamperone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipamperone.Approved
MethotrimeprazinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Pipamperone.Approved, Investigational, Vet Approved
MethoxyphenaminePipamperone may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pipamperone.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pipamperone.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Pipamperone.Approved
MetipranololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pipamperone.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metoprolol.Approved, Investigational
MetyrosinePipamperone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pipamperone.Approved, Illicit
MidomafetaminePipamperone may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pipamperone is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Minoxidil.Approved, Investigational
MirtazapinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAPipamperone may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pipamperone.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Pipamperone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pipamperone.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Pipamperone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pipamperone.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Pipamperone.Approved, Investigational
NebivololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Pipamperone.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Pipamperone.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pipamperone.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Pipamperone.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pipamperone.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nitrous acid.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pipamperone.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pipamperone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Pipamperone.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pipamperone.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pipamperone.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Pipamperone.Approved
OpiumThe risk or severity of adverse effects can be increased when Pipamperone is combined with Opium.Approved, Illicit
OrphenadrinePipamperone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Pipamperone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipamperone.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Pipamperone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pipamperone.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pipamperone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pipamperone.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pipamperone.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pipamperone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Papaverine.Approved, Investigational
ParaldehydePipamperone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pipamperone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Pipamperone.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PerazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Pipamperone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pipamperone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pipamperone.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Pipamperone.Approved
PhenibutThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Pipamperone.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Pipamperone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Phenoxyethanol.Approved
PhenterminePipamperone may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Pipamperone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Pipamperone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pipamperone.Approved
PindololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pindolol.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pipamperone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Pipamperone.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pipamperone.Approved
PramipexolePipamperone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Prazosin.Approved
PregabalinThe therapeutic efficacy of Pipamperone can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Pipamperone.Approved
PrimidonePrimidone may increase the hypotensive activities of Pipamperone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Pipamperone.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Pipamperone.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pipamperone.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Pipamperone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pipamperone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipamperone.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pipamperone is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Pipamperone.Investigational
PseudoephedrinePipamperone may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pipamperone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pipamperone.Approved
QuinagolideThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Quinagolide.Approved, Investigational
QuinaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinapril.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pipamperone.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipamperone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Pipamperone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pipamperone.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Pipamperone is combined with Riociguat.Approved
RisperidonePipamperone may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Ritanserin.Investigational
RitobegronPipamperone may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Pipamperone.Approved
RomifidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Romifidine.Vet Approved
RopinirolePipamperone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Pipamperone.Approved
RotigotinePipamperone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pipamperone.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sacubitril.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pipamperone.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pipamperone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Pipamperone.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipamperone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
SotalolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Pipamperone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Pipamperone is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.Approved, Investigational
SulpiridePipamperone may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Pipamperone.Approved, Investigational
SuvorexantPipamperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Pipamperone.Approved, Investigational
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Pipamperone.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pipamperone.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pipamperone.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Pipamperone.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Pipamperone.Investigational
ThalidomidePipamperone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipamperone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Pipamperone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pipamperone.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pipamperone.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tilidine.Experimental
TimololThe risk or severity of adverse effects can be increased when Pipamperone is combined with Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tizanidine.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe therapeutic efficacy of Pipamperone can be decreased when used in combination with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pipamperone.Approved
TorasemideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pipamperone.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Pipamperone.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipamperone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pipamperone.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pipamperone is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pipamperone.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Pipamperone is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Pipamperone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pipamperone.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pipamperone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Pipamperone.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Pipamperone is combined with Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pipamperone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pipamperone is combined with Veralipride.Experimental
VerapamilThe risk or severity of adverse effects can be increased when Pipamperone is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pipamperone.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Pipamperone.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pipamperone is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipamperone.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Pipamperone is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pipamperone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pipamperone.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Pipamperone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pipamperone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipamperone.Approved, Investigational
ZolpidemPipamperone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pipamperone.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pipamperone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Pipamperone.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pipamperone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Prinssen EP, Koek W, Kleven MS: The effects of antipsychotics with 5-HT(2C) receptor affinity in behavioral assays selective for 5-HT(2C) receptor antagonist properties of compounds. Eur J Pharmacol. 2000 Jan 24;388(1):57-67. [PubMed:10657547]
  2. Wainscott DB, Lucaites VL, Kursar JD, Baez M, Nelson DL: Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther. 1996 Feb;276(2):720-7. [PubMed:8632342]
  3. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
  4. Wade AG, Crawford GM, Nemeroff CB, Schatzberg AF, Schlaepfer T, McConnachie A, Haazen L, Buntinx E: Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response. Psychol Med. 2011 Oct;41(10):2089-97. doi: 10.1017/S0033291711000158. Epub 2011 Feb 25. [PubMed:21349239]
  5. Gareri P, De Fazio P, Stilo M, Ferreri G, De Sarro G: Conventional and atypical antipsychotics in the elderly : a review. Clin Drug Investig. 2003;23(5):287-322. [PubMed:17535043]
  6. Van Craenenbroeck K, Gellynck E, Lintermans B, Leysen JE, Van Tol HH, Haegeman G, Vanhoenacker P: Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor. Life Sci. 2006 Dec 3;80(1):74-81. doi: 10.1016/j.lfs.2006.08.024. Epub 2006 Aug 25. [PubMed:16978659]
  7. Wijma RA, van der Nagel BC, Dierckx B, Dieleman GC, Touw DJ, van Gelder T, Koch BC: Identification and quantification of the antipsychotics risperidone, aripiprazole, pipamperone and their major metabolites in plasma using ultra-high performance liquid chromatography-mass spectrometry. Biomed Chromatogr. 2016 Jun;30(6):794-801. doi: 10.1002/bmc.3610. Epub 2015 Oct 8. [PubMed:26447610]
  8. Squelart P, Saravia J: Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome chronic psychotic patients. Acta Psychiatr Belg. 1977 Mar-Apr;77(2):284-93. [PubMed:906888]
  9. Pipamperone [Link]
  10. The Treatment of Autism with Pipamperone [Link]
  11. Pipamperone [Link]
  12. Pipamperone: International drug information [Link]
  13. Low dose pipamperone in treatment mood disorders [Link]
  14. Pipamperone dihydrochloride [Link]
  15. The Pharmacological Role and Clinical Applications of Antipsychotics’ Active Metabolites: Paliperidone versus Risperidone [Link]
  16. Pipamerone [Link]
  17. Pipamperone and increased excercise/weight [Link]
  18. Current antipsychotics [Link]
  19. Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders [Link]
  20. PP232—Acute toxicity profile of pipamperone in overdose: A consecutive case series [Link]
External Links
KEGG Drug
D02622
PubChem Compound
4830
PubChem Substance
310265179
ChemSpider
4664
BindingDB
81483
ChEBI
78549
ChEMBL
CHEMBL440294
Wikipedia
Pipamperone
ATC Codes
N05AD05 — Pipamperone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentChronic Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentDepression1
3CompletedTreatmentMajor Depressive Disorder (MDD)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)>254https://www.trc-canada.com/product-detail/?P475200
water solubilitysoluble in methanolhttps://www.trc-canada.com/product-detail/?P475200
logP2.02https://comptox.epa.gov/dashboard/dsstoxdb/results?search=Pipamperone
Predicted Properties
PropertyValueSource
Water Solubility0.182 mg/mLALOGPS
logP2.32ALOGPS
logP1.87ChemAxon
logS-3.3ALOGPS
pKa (Strongest Acidic)15.94ChemAxon
pKa (Strongest Basic)8.69ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.64 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.1 m3·mol-1ChemAxon
Polarizability41.16 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Phenylbutylamines / Butyrophenones / Piperidinecarboxamides / Aryl alkyl ketones / Benzoyl derivatives / Aminopiperidines / Fluorobenzenes / Aryl fluorides / Gamma-amino ketones / Trialkylamines
show 6 more
Substituents
Alkyl-phenylketone / Butyrophenone / Phenylbutylamine / Piperidinecarboxamide / Benzoyl / Aryl alkyl ketone / Fluorobenzene / 4-aminopiperidine / Halobenzene / Aryl fluoride
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, tertiary amino compound, monocarboxylic acid amide, aromatic ketone, bipiperidines (CHEBI:78549)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation...
Gene Name
HTR2B
Uniprot ID
P41595
Uniprot Name
5-hydroxytryptamine receptor 2B
Molecular Weight
54297.41 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. [PubMed:8935801]

Drug created on October 29, 2015 12:11 / Updated on June 02, 2018 09:36